ImmunityBio, Inc. IBRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total equity?
- ImmunityBio, Inc. (IBRX) reported total equity of -$870.01M in Q1 2026.
- How has ImmunityBio, Inc.'s total equity changed year-over-year?
- ImmunityBio, Inc.'s total equity decreased by 47.1% year-over-year, from -$591.43M to -$870.01M.
- What is the long-term trend for ImmunityBio, Inc.'s total equity?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total equity has grown at a 33.1% compound annual growth rate (CAGR), from -$119.81M to -$500.47M.
- What does total equity mean?
- The total value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- Higher equity generally indicates a stronger financial position and lower reliance on debt financing.
- How does total equity compare across companies?
- Crucial for assessing solvency in capital-intensive biotech firms.